The Metabolomic Core provides investigators with a resource that facilitates the analysis of major metabolic pathways in humans, animals, and in vitro systems. The analytical repertoire includes the measurement – both in vivo and in vitro – of flux through major pathways of intermediary metabolism, including glycolysis, the tricarboxylic acid cycle, the oxidation of fatty acids and amino acids, the urea cycle and protein synthesis and degradation; determination of in vivo metabolic rate in freely moving organisms; and determination of selected drugs and/or drug metabolites with triple-stage quadruple mass spectrometry.
The Bioanalysis Core specializes in developing and validating robust liquid chromatography/tandem mass spectrometry methods for the analysis of natural products, drugs, and metabolites in various biological samples (blood, DBS, plasma, urine and tissue). The core has extensive experience in method development and validation. Despite the analytical complexity, it approaches every compound with creativity, innovation, and years of scientific knowledge, allowing core personnel to uncover solutions to complex bioanalytical challenges.
The Bioanalysis Core performs method validations, partial validations, cross-matrix validations, or combination of them required to meet project needs. Validation studies are performed in accordance with the US FDA Guidance for Industry, Bioanalytical Method Validation. The core has developed assays for investigational and marketed drugs used for pain, oncology, cardiology and infectious diseases. These assays are typically used to support pediatric drug discovery and development.